ARKG - Can Invitae Be the Winner-Take-Most in Genetic Testing?
Well, probably not all the chips, but taking home most of them is certainly possible. Cathie Wood of ARK investment Management has described Invitae (NYSE: NVTA) as operating in a "winner-take-most" market, and identified Invitae as one of the most under-appreciated companies in her ETFs . Invitae is a top 20 holding across the ARK Innovation ETF (NYSEMKT: ARKK) and ARK Genomic Revolution ETF (NYSEMKT: ARKG) . Does it belong in your portfolio too?
Image source: Getty Images
The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers offer undifferentiated products, and profits are driven down by the forces of competition. Think of almost anything you see on a grocery store shelf.
For further details see:
Can Invitae Be the Winner-Take-Most in Genetic Testing?